Clinical Trials Logo
  1. Home
  2. Epilepsy, Complex Partial
  3. NCT03156439

Bioavailability, Safety, and Tolerability of BIS-001 ER

Epilepsy, Complex Partial Clinical Trial

Official title:
Evaluation of the Bioavailability, Safety, and Tolerability of BIS-001 ER Following Multiple Dose Administration in Healthy Subjects

Clinical Trial Summary

This study investigates the safety, tolerability, and pharmacokinetics of BIS-001 ER in healthy volunteers. Subjects will be dosed twice daily, with a dose escalation occurring every 2-3 days until a maximum dose of 5mg per day is reached.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03156439
Study type Interventional
Source Biscayne Neurotherapeutics, Inc.
Contact
Status Completed
Phase Phase 1
Start date May 22, 2017
Completion date September 30, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT00143143 - Pregabalin Open-Label Extension Trial in Patients With Partial Seizures Phase 3
Completed NCT01002820 - A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601 Phase 2
Completed NCT00001489 - Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism N/A
Completed NCT00433667 - A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. Phase 3
Completed NCT00425282 - A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. Phase 3
Completed NCT04573569 - Neural Correlates of Cognition and Mood
Completed NCT00740623 - A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures. Phase 3
Completed NCT00744731 - An Open-Label Extension Study of the Safety and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures Phase 3
Completed NCT00319501 - Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control Episodes of Acute Repetitive Seizures. Phase 3
Completed NCT00991757 - An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures. Phase 3
Completed NCT00056576 - Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy Phase 3
Terminated NCT01128712 - Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin Phase 4